CytoMed Therapeutics (NASDAQ:GDTC) Issues Quarterly Earnings Results

CytoMed Therapeutics (NASDAQ:GDTC) announced its quarterly earnings results on Wednesday, September 30th. The company reported $0.05 earnings per share (EPS) for the quarter, reports. The business had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Stock Down 1.0%

Shares of GDTC traded down $0.01 during trading hours on Friday, hitting $0.86. The company had a trading volume of 3,325 shares, compared to its average volume of 213,326. The stock’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.97. CytoMed Therapeutics has a 52-week low of $0.68 and a 52-week high of $3.68.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GDTC shares. Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Friday, October 2nd. Fundamental Research set a $4.16 price objective on CytoMed Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CytoMed Therapeutics has an average rating of “Hold” and an average price target of $4.16.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research programs are designed to use immune cells to recognize and attack cancer cells, with an emphasis on potentially scalable, off-the-shelf treatments.

CytoMed’s technology platform includes the development of allogeneic cell therapies derived from healthy donors, including therapies based on gamma-delta T cells and other immune-cell types.